Rechberger T, et al. - In this multicenter, randomized, double-blind, placebo- and active-controlled trial, meloxicam intravenous (IV), an investigational product not yet approved by the US Food and Drug Administration, was tested for its safety and efficacy in providing analgesia following open abdominal hysterectomy. This study included 486 women who experienced moderate-to-severe pain following open abdominal hysterectomy. These subjects were randomly allocated to receive a single dose of meloxicam IV (5–60 mg), placebo, or morphine (0.15 mg/kg) in ≤6 hours following morphine dosing on postoperative day 1. Study participants generally well tolerated a meloxicam IV dose of 5–60 mg, which seemed to attenuate opioid consumption in these patients. Analgesic effect of meloxicam IV, given once-daily, was evident within 6–8 minutes postdose and was maintained over a 24-hour dosing interval.